CLYM — Climb Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1768446 ·
Last close
$9.78
Market Cap
$574.46M
52W High
$18.33
52W Low
$1.63
ADV30
1,169,835
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -16,893,000 | -14,573,000 | 236,564,000 | 39,731,000 | 8,511,000 |
| Jun 2026 | 0 | — | -15,359,000 | -13,498,000 | 246,294,000 | 44,107,000 | 6,747,000 |
| Mar 2026 | 0 | — | -15,211,000 | -13,722,000 | 152,372,000 | 8,356,000 | 4,287,000 |
| Dec 2025 | 0 | — | -19,296,000 | -17,516,000 | 167,744,000 | 35,685,000 | 7,269,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-52,560,000
Investing CF
$-38,280,000
Financing CF
$104,911,000
CapEx
$-929,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-331,520,000
Inventory
—
Receivables
$1,366,000
ST Investments
$165,692,000
EBIT TTM
$-66,759,000
Pretax Income TTM
$-59,309,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -67,883,000 | -59,851,000 | 167,744,000 | 7,269,000 | 160,475,000 | -54,356,000 |
| Dec 2024 | 0 | -30,361,000 | -73,897,000 | 217,187,000 | 5,306,000 | 211,881,000 | -15,562,000 |
| Dec 2023 | 0 | -40,275,000 | -35,119,000 | 110,469,000 | 2,870,000 | 107,599,000 | -20,599,000 |
| Dec 2022 | 0 | -45,135,000 | -45,244,000 | 134,992,000 | 6,277,000 | 128,715,000 | -37,369,000 |
TTM Snapshot
Revenues TTM
$9,519,000
NetIncome TTM
$-57,624,000
OpCashFlow TTM
—
Assets (Latest)
$246,294,000
Forward EPS
$-1.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| WVE | Wave Life Sciences, Inc. | $560.13M | $2.84 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $559.34M | $9.40 | — |
| EVOTF | Evotec SE | $590.83M | $3.33 | — |
| ANL | Adlai Nortye Group Ltd. | $556.80M | $9.48 | — |
| AVBP | ArriVent BioPharma, Inc. | $552.92M | $10.69 | — |
News headlines (Yahoo Finance, 1h cache)
Wedbush keeps Climb Bio on Best Ideas List, raises price target
2026-11-06 16:58 · Yahoo
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-05 12:00 · Yahoo
Wedbush Says This Stock Remains a Top Pick Despite Recent Volatility
2026-11-04 16:24 · Yahoo
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
2026-11-04 14:00 · Yahoo
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-02 12:00 · Yahoo
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
2026-10-24 23:30 · Yahoo
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
2026-10-23 20:01 · Yahoo
Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline
2026-10-20 15:14 · Yahoo
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
2026-10-20 12:40 · Yahoo
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
2026-10-02 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.